474PA novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. (23rd October 2018) - Seufferlein, T; Lausser, L; Stein, A; Prager, G; Kasper, S; Niedermeier, M; Müller, L; Kubicka, S; König, A-O; Büchner-Steudel, P; Wille, K; Perkhofer, L; et al.